Edwards Lifesciences (EW) and DexCom (DXCM) Annouce Receipt of CE Mark
More News related to DXCM
- DexCom To Present at the Piper Jaffray 21st Annual Health Care Conference
- DexCom Appoints Nicholas Augustinos as Board Member
- DexCom To Present at Lazard Capital Markets 6th Annual Healthcare Conference
- DexCom (DXCM) Posts Q3 Loss of 29c, Beats by 3c
- DexCom Inc. Reports Third Quarter 2009 Financial Results
More News related to EW
- Morgan Joseph Initiates Coverage on Edwards Lifesciences (EW) with a Hold; High-Quality Mid-Cap Growth Name
- Edwards Lifesciences Honors Dr. William Ganz' Contributions to Patient Care
- The Edwards Lifesciences Fund to Grant $4.6 Million to Nonprofit Organizations in 2009
- First Transcatheter Valve Cases in Japan Performed With Edwards SAPIEN Valve
- Edwards Lifesciences to Present at the Credit Suisse Annual Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) and DexCom, Inc. (NASDAQ: DXCM) today announced the receipt of CE Mark for an automatic glucose monitoring system.
Edwards and DexCom co-developed this new system, which is indicated for automatic, real-time monitoring and trending of blood glucose concentration in critically ill adults in the hospital environment. This CE Mark allows for commercialization of the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark. Market evaluations of a first generation product are expected to begin in a limited number of European sites before the end of the year.
Studies have shown that hospitalized patients can be at a higher risk of infection and other complications if their blood glucose level is elevated for prolonged periods. Currently, clinicians manage patients' glucose levels by manually obtaining intermittent samples over various periods of time. Methods for obtaining blood samples can be labor intensive and may not provide complete information about a patient's glucose status. This glucose monitoring system will perform multiple automatic readings per hour that may provide a new level of trending insight designed to enable clinicians to effectively implement glycemic control.
Related Categories
Corporate NewsStocks Mentioned
-0.27Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
